NASDAQ:ERAS Erasca - ERAS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.04 +0.13 (+3.32%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.90▼$4.1150-Day Range$3.75▼$7.6152-Week Range$3.60▼$12.80Volume1.00 million shsAverage Volume922,131 shsMarket Capitalization$494.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Erasca MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy11.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 2 Articles This WeekInsider TradingAcquiring Shares$2.57 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.20) to ($1.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.98 out of 5 starsMedical Sector693rd out of 1,055 stocksPharmaceutical Preparations Industry351st out of 519 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Erasca. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.62% of the float of Erasca has been sold short.Short Interest Ratio / Days to CoverErasca has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Erasca has recently decreased by 22.94%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldErasca does not currently pay a dividend.Dividend GrowthErasca does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ERAS. Previous Next 3.9 News and Social Media Coverage News SentimentErasca has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Erasca this week, compared to 1 article on an average week.Search Interest4 people have searched for ERAS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows2 people have added Erasca to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Erasca insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,574,998.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders37.50% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.75% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Erasca are expected to decrease in the coming year, from ($1.20) to ($1.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Erasca is -3.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Erasca is -3.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErasca has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Erasca (NASDAQ:ERAS) StockErasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.Read More Receive ERAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter. Email Address ERAS Stock News HeadlinesJanuary 21, 2023 | americanbankingnews.comHead to Head Survey: Erasca (NASDAQ:ERAS) and Longboard Pharmaceuticals (NASDAQ:LBPH)January 16, 2023 | finance.yahoo.comWe Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business GrowthJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 11, 2023 | benzinga.comErasca Chairman & CEO Makes $231K Stock PurchaseJanuary 4, 2023 | finance.yahoo.comErasca to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 20, 2022 | finance.yahoo.comErasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid TumorsDecember 17, 2022 | finance.yahoo.comCo-Founder Jonathan Lim Just Bought A Handful Of Shares In Erasca, Inc. (NASDAQ:ERAS)December 16, 2022 | finance.yahoo.comErasca, Inc.'s (NASDAQ:ERAS) recent 16% pullback adds to one-year year losses, institutional owners may take drastic measuresJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 13, 2022 | msn.comErasca receives FDA clearance to begin trial of non-small cell lung cancer treatmentDecember 13, 2022 | finance.yahoo.comErasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid TumorsDecember 9, 2022 | marketwatch.comErasca Shares Drop 30% After Pricing of $100M Underwritten Offering, Novartis AgreementDecember 9, 2022 | markets.businessinsider.comErasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity OfferingDecember 9, 2022 | seekingalpha.comErasca to pay $20M upfront to Novartis in license deal for potential cancer drugNovember 30, 2022 | markets.businessinsider.comErasca To Work With Pierre Fabre To Explore ERAS-007 In Combination With Encorafenib, CetuximabNovember 30, 2022 | finance.yahoo.comErasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib CombinationNovember 22, 2022 | finance.yahoo.comErasca to Present at Upcoming Investor ConferencesNovember 14, 2022 | finance.yahoo.comWall Street Analysts Predict a 126% Upside in Erasca, Inc. (ERAS): Here's What You Should KnowNovember 13, 2022 | finanznachrichten.deErasca, Inc.: Erasca Reports Third Quarter 2022 Financial Results and Business UpdatesNovember 9, 2022 | finance.yahoo.comErasca Reports Third Quarter 2022 Financial Results and Business UpdatesOctober 20, 2022 | finance.yahoo.comErasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib CombinationOctober 12, 2022 | finance.yahoo.comErasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR SymposiumSeptember 26, 2022 | finance.yahoo.comErasca to Present at the Bank of America Securities Precision Oncology Conference 2022September 8, 2022 | msn.comPeering Into Erasca's Recent Short InterestSeptember 7, 2022 | finance.yahoo.comErasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination TrialsAugust 24, 2022 | finance.yahoo.comErasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid TumorsAugust 23, 2022 | finance.yahoo.comErasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven CancersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ERAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter. Email Address ERAS Company Calendar Last Earnings11/09/2022Today1/28/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ERAS CUSIPN/A CIK1761918 Webwww.erasca.com Phone858-465-6511FaxN/AEmployees123Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-122,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.63% Return on Assets-29.55% Debt Debt-to-Equity RatioN/A Current Ratio13.21 Quick Ratio13.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.77 per share Price / Book1.07Miscellaneous Outstanding Shares122,360,000Free Float76,476,000Market Cap$494.33 million OptionableNot Optionable Beta1.27 Key ExecutivesDr. Jonathan E. Lim M.D. (Age 51)Co-Founder, Chairman & CEO Comp: $850.23kMr. Ebun S. Garner J.D. (Age 51)Esq., Gen. Counsel & Corp. Sec. Comp: $510.98kDr. Wei Lin M.D. (Age 53)Chief Medical Officer Comp: $1MDr. Michael D. Varney Ph.D. (Age 65)Chairman of R&D, Scientific Advisory Board Member and Director Comp: $78.38kDr. David M. Chacko M.D. (Age 39)Chief Financial Officer Dr. Nik Chetwyn Ph.D.Sr. VP of OperationsDr. Lisa Tesvich-Bonora Ph.D.Chief People OfficerMr. Brian L. Baker CPA (Age 56)M.S., MS, CPA, Sr. VP of Fin. Ms. Chandra D. Lovejoy (Age 52)Sr. VP of Regulatory Affairs Dr. Robert Shoemaker Ph.D. (Age 42)Sr. VP of Research More ExecutivesKey Competitors2seventy bioNASDAQ:TSVTProcaps GroupNASDAQ:PROCGH ResearchNASDAQ:GHRSAkouosNASDAQ:AKUSKezar Life SciencesNASDAQ:KZRView All CompetitorsInsiders & InstitutionsJonathan E LimBought 60,000 shares on 1/10/2023Total: $231,600.00 ($3.86/share)Valerie Denise Harding StartBought 10,000 shares on 12/21/2022Total: $46,400.00 ($4.64/share)Alexander W CasdinBought 20,000 shares on 12/15/2022Total: $97,400.00 ($4.87/share)Jonathan E LimBought 40,000 shares on 12/14/2022Total: $199,600.00 ($4.99/share)Bihua ChenBought 307,692 shares on 12/13/2022Total: $2.00 M ($6.50/share)View All Insider TransactionsView All Institutional Transactions ERAS Stock - Frequently Asked Questions How have ERAS shares performed in 2023? Erasca's stock was trading at $4.31 on January 1st, 2023. Since then, ERAS shares have decreased by 6.3% and is now trading at $4.04. View the best growth stocks for 2023 here. Are investors shorting Erasca? Erasca saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 8,060,000 shares, a decrease of 22.9% from the December 31st total of 10,460,000 shares. Based on an average daily volume of 1,070,000 shares, the short-interest ratio is presently 7.5 days. Approximately 11.6% of the shares of the company are sold short. View Erasca's Short Interest. When is Erasca's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our ERAS earnings forecast. How were Erasca's earnings last quarter? Erasca, Inc. (NASDAQ:ERAS) released its earnings results on Wednesday, November, 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.02. When did Erasca IPO? (ERAS) raised $262 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share. What is Erasca's stock symbol? Erasca trades on the NASDAQ under the ticker symbol "ERAS." How do I buy shares of Erasca? Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Erasca's stock price today? One share of ERAS stock can currently be purchased for approximately $4.04. How much money does Erasca make? Erasca (NASDAQ:ERAS) has a market capitalization of $494.34 million. The company earns $-122,760,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. How many employees does Erasca have? The company employs 123 workers across the globe. How can I contact Erasca? The official website for the company is www.erasca.com. The company can be reached via phone at 858-465-6511 or via email at ir@erasca.com. This page (NASDAQ:ERAS) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.